NDAC's Nov. 20-22 meeting to focus on vaginal contraceptive efficacy; STD prevention.
This article was originally published in The Tan Sheet
Executive Summary
NDAC TO ADDRESS SPERMICIDAL EFFICACY DURING NOV. 20-22 JOINT MEETING with the Anti-Infective Drugs and Antiviral Drugs Advisory Committees and the Advisory Committee for Reproductive Health, formerly known as the Fertility and Maternal Health Advisory Committee. The Nonprescription Drugs Advisory Committee and the other groups are scheduled to consider the role of vaginal contraceptives in preventing HIV and chlamydia, and to discuss FDA's 1995 proposed rule for OTC vaginal contraceptives.